Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Postmarketing Observational Study to Evaluate the Effect of Zemplar (Paricalcitol IV) on Cardiac Morbidity in Patients With Chronic Kidney Disease Stage 5 Over 2 Years.

NCT01073462 is registered in ClinicalTrials.gov with AbbVie (prior sponsor, Abbott) as lead sponsor.

NCT NCT01073462
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01073462 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Postmarketing Observational Study to Evaluate the Effect of Zemplar (Paricalcitol IV) on Cardiac Morbidity in Patients With Chronic Kidney Disease Stage 5 Over 2 Years.
Lead sponsor
AbbVie (prior sponsor, Abbott)
Phase
Observational
Overall status
Completed
Start date
December 31, 2008
Completion date
June 30, 2013
Enrollment
67 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

cardiac morbidity, chronic kidney disease stage v, secondary hyperparathyroidism